Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2

Metastatic pancreatic cancer (PC) has been associated with a considerably poor prognosis. Due to its toxicity, first-line combination chemotherapy is limited to patients with a good performance status (PS). Previously nab-paclitaxel plus gemcitabine has been demonstrated to improve the overall survi...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2016-07, Vol.12 (1), p.727-730
Main Authors: MARTÍN, ANDRÉS J. MUÑOZ, ALFONSO, PILAR GARCÍA, RUPÉREZ, ANA B, JIMÉNEZ, MIGUEL MARTÍN
Format: Article
Language:English
Subjects:
Analgesics
Anemia
Breast cancer
CA19-9
Cancer therapies
Chemotherapy
Diagnosis
Drug therapy
Gemcitabine
Gene amplification
Lymphatic system
Medical prognosis
Metastasis
Mortality
nab-paclitaxel plus gemcitabine
Oncology
Paclitaxel
Pain
palliative therapy
pancreatic adenocarcinoma
Pancreatic cancer
Patient outcomes
Patients
poor performance status
Radiation therapy
Surgery
tolerance
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic pancreatic cancer (PC) has been associated with a considerably poor prognosis. Due to its toxicity, first-line combination chemotherapy is limited to patients with a good performance status (PS). Previously nab-paclitaxel plus gemcitabine has been demonstrated to improve the overall survival rate in patients with advanced pancreatic cancer with a good PS. The present study reports a case of a patient with metastatic PC with a poor PS (Eastern Cooperative Oncology Group 2) and a complex set of comorbidities treated with nab-paclitaxel plus gemcitabine as a first-line palliative therapy. Adjusted doses of nab-paclitaxel plus gemcitabine reached a favourable clinical, radiological and biochemical response in the present patient, which increased the quality of life for the patient. Eventually, the patient succumbed to acute cholangitis. Based on the results of the present study, nab-paclitaxel plus gemcitabine appears to be a favourable treatment as first-line palliative chemotherapy for patients with metastatic PC, comorbidities and poor PS.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2016.4667